

LIDDS strengthens the organization with two new recruitments

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company has recruited Annette Møldrup as Chief Business Development Officer and Kia Bengtsson as Head of Clinical Development. Both have extensive experience from the pharmaceutical industry and will assume their new roles in the autumn 2022.

"This is an important step for LIDDS' future development and I am very happy to welcome Annette and Kia to the company. With Annette's business development experience we will take an important step towards increasing our ability to negotiate and realize deals and also improve the awareness about LIDDS internationally. Through Kia we will get strong contribution to the clinical development of our portfolio." says Nina Herne, CEO of LIDDS.

Annette Møldrup has long experience from the pharmaceutical industry where she has worked within global business development at Novo Nordisk and most recently at Ferring. Annette will be part of the management team. She has a Cand.Scient of Biochemistry and PhD of Molecular and Cellular Biology from University of Copenhagen. Annette assumes her new role on September 1, 2022.

Kia has 25 years experience from clinical development from among others AstraZeneca, Nanologica, Eurocine Vaccines and Ipsen. She comes most recently from the role as Head of Clinical Development at Vivesto. Kia is a registered nurse from the Karolinska Institute and assumes her new role on October 1, 2022

For additional information, please contact

Nina Herne, CEO
Phone: +46 (0)70 714 74 57
E-mail: nina.herne@liddspharma.com

Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS' Certified Adviser is Redeye AB
Tel: +46 (0)8 121 576 90
E-mail: certifiedadviser@redeye.se

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS strengthens the organization with two new recruitments